Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NASDAQ:HRTX NASDAQ:MIST NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$2.08+11.2%$1.94$0.40▼$2.66$251.63M0.411.15 million shs998,733 shsHRTXHeron Therapeutics$1.21-2.4%$0.97$0.74▼$2.30$233.91M1.72.30 million shs1.79 million shsMISTMilestone Pharmaceuticals$1.92+1.6%$1.69$1.00▼$3.06$226.12M1.041.58 million shs601,716 shsSCLXScilex$7.82-2.7%$7.63$3.92▼$34.27$68.27M1.7795,488 shs112,534 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-10.53%+10.00%+2.19%-8.78%+292.03%HRTXHeron Therapeutics-5.34%+3.33%+57.08%-1.59%-45.01%MISTMilestone Pharmaceuticals-4.06%+5.00%+17.39%+7.39%+47.08%SCLXScilex-15.37%-23.57%+14.53%-5.30%+74.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$2.08+11.2%$1.94$0.40▼$2.66$251.63M0.411.15 million shs998,733 shsHRTXHeron Therapeutics$1.21-2.4%$0.97$0.74▼$2.30$233.91M1.72.30 million shs1.79 million shsMISTMilestone Pharmaceuticals$1.92+1.6%$1.69$1.00▼$3.06$226.12M1.041.58 million shs601,716 shsSCLXScilex$7.82-2.7%$7.63$3.92▼$34.27$68.27M1.7795,488 shs112,534 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-10.53%+10.00%+2.19%-8.78%+292.03%HRTXHeron Therapeutics-5.34%+3.33%+57.08%-1.59%-45.01%MISTMilestone Pharmaceuticals-4.06%+5.00%+17.39%+7.39%+47.08%SCLXScilex-15.37%-23.57%+14.53%-5.30%+74.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.67Moderate Buy$4.60121.15% UpsideHRTXHeron Therapeutics 2.20Hold$4.50271.90% UpsideMISTMilestone Pharmaceuticals 2.67Moderate Buy$7.50290.63% UpsideSCLXScilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCLX, ALXO, HRTX, and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026MISTMilestone Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$6.004/9/2026MISTMilestone Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy3/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/19/2026ALXOALX Oncology Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$5.003/10/2026ALXOALX Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/6/2026ALXOALX Oncology UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.002/26/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell2/24/2026MISTMilestone Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$0.48 per shareN/AHRTXHeron Therapeutics$154.90M1.47N/AN/A$0.07 per share17.29MISTMilestone Pharmaceuticals$1.55M148.20N/AN/A$0.39 per share4.92SCLXScilex$30.25M2.19N/AN/A($24.94) per share-0.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$101.69M-$1.90N/AN/AN/AN/A-182.01%-113.63%5/8/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.13N/A10.08N/A-13.04%N/A-4.62%5/11/2026 (Estimated)MISTMilestone Pharmaceuticals-$63.06M-$0.79N/AN/AN/AN/A-656.73%-81.19%5/13/2026 (Estimated)SCLXScilex-$358.73M-$36.45N/AN/AN/A-1,185.78%N/A-178.57%6/3/2026 (Estimated)Latest SCLX, ALXO, HRTX, and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/ASCLXScilex-$0.3373N/AN/AN/A$15.00 millionN/A5/13/2026Q1 2026MISTMilestone Pharmaceuticals$0.19N/AN/AN/A$30.12 millionN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03N/AN/AN/A$36.72 millionN/A5/8/2026Q1 2026ALXOALX Oncology-$0.15-$0.17-$0.02-$0.17N/AN/A4/10/2026Q4 2025SCLXScilex-$0.47-$4.60-$4.13-$4.60$12.10 million$4.79 million3/20/2026Q4 2025MISTMilestone Pharmaceuticals-$0.18-$0.16+$0.02-$0.16$37.52 million$1.44 million3/9/2026Q4 2025ALXOALX OncologyN/A-$0.42N/A-$0.42N/AN/A2/27/2026Q4 2025ALXOALX Oncology-$0.38-$0.42-$0.04-$0.42N/AN/A2/26/2026Q4 2025HRTXHeron Therapeutics-$0.03-$0.02+$0.01-$0.02$39.53 million$40.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.172.072.07HRTXHeron Therapeutics10.592.481.51MISTMilestone Pharmaceuticals1.378.017.96SCLXScilexN/A0.080.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%HRTXHeron Therapeutics80.01%MISTMilestone Pharmaceuticals86.18%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%HRTXHeron Therapeutics5.86%MISTMilestone Pharmaceuticals19.50%SCLXScilex4.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology40134.56 million106.30 millionOptionableHRTXHeron Therapeutics300188.64 million177.59 millionOptionableMISTMilestone Pharmaceuticals30119.64 million96.31 millionOptionableSCLXScilex808.49 million8.14 millionNo DataSCLX, ALXO, HRTX, and MIST HeadlinesRecent News About These CompaniesPHOE stock more than doubles on strategic pivot into pharma industry with Scilex dealMay 5 at 8:01 PM | msn.comScilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings LimitedMay 5 at 3:00 PM | theglobeandmail.comScilex Subsidiary Reshapes Phoenix Asia via $1B Share DealMay 5 at 1:51 PM | tipranks.comScilex Holding Company Announces Acquisition Agreement Between ACEA Therapeutics and Phoenix Asia HoldingsMay 5 at 1:11 PM | quiverquant.comQScilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to ...May 4, 2026 | markets.businessinsider.comScilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026May 4, 2026 | globenewswire.comScilex Holding Company (NASDAQ:SCLX) Short Interest Down 15.4% in AprilMay 3, 2026 | americanbankingnews.comScilex (NASDAQ:SCLX) Downgraded to "Strong Sell" Rating by Wall Street ZenMay 2, 2026 | marketbeat.comShort Interest in Scilex Holding Company (NASDAQ:SCLX) Decreases By 15.4%May 1, 2026 | marketbeat.comScilex Plans Major Investment in Datavault Quantum-Ready NetworkApril 28, 2026 | tipranks.comDatavault AI (NASDAQ: DVLT) Executes $120M Term Sheet With Scilex for Quantum-Ready Edge Network DeploymentApril 27, 2026 | usatoday.comDatavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum PlatformApril 27, 2026 | businesswire.comScilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026April 20, 2026 | globenewswire.comScilex (NASDAQ:SCLX) Announces Earnings ResultsApril 11, 2026 | marketbeat.comScilex Delays 2025 Annual 10-K FilingApril 1, 2026 | tipranks.comScilex Files Federal Lawsuit Over Misappropriated Datavault CollateralMarch 13, 2026 | tipranks.comScilex Holding Company Files Complaint Over Alleged Unauthorized Sale of $100 Million in Pledged SharesMarch 13, 2026 | quiverquant.comQScilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd.March 13, 2026 | globenewswire.comScilex Files Securities Fraud Suit Over Stock LoanMarch 13, 2026 | tipranks.comScilex Grants Oramed New Warrant in Financing AgreementFebruary 20, 2026 | tipranks.comDatavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026February 5, 2026 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCLX, ALXO, HRTX, and MIST Company DescriptionsALX Oncology NASDAQ:ALXO$2.08 +0.21 (+11.23%) Closing price 04:00 PM EasternExtended Trading$1.98 -0.10 (-4.81%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Heron Therapeutics NASDAQ:HRTX$1.21 -0.03 (-2.42%) Closing price 04:00 PM EasternExtended Trading$1.23 +0.02 (+1.24%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Milestone Pharmaceuticals NASDAQ:MIST$1.92 +0.03 (+1.59%) Closing price 04:00 PM EasternExtended Trading$1.92 +0.00 (+0.21%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Scilex NASDAQ:SCLX$7.82 -0.22 (-2.74%) Closing price 04:00 PM EasternExtended Trading$7.86 +0.04 (+0.58%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
